IL-6靶向治疗炎症性疾病和Castleman病的研究进展  

Interleukin-6 as a Therapeutic Target on inflammatory disease and Castleman's disease

作　　者：禹博[1] 黄素辉[1] 张桐硕[1] 王越[1] YU Bo HUANG Su-hui ZHANG Tong-shuo WANG Yue(Department of Pathogenic Biology and Immunology, Logistics University of PAP, Tianjin 300309, Chin)

机构地区：[1]武警后勤学院病原生物与免疫学教研室,天津300309

出　　处：《武警后勤学院学报（医学版）》2017年第7期634-636,640,共4页Journal of Logistics University of PAP（Medical Sciences）

基　　金：国家自然科学基金项目(81273520;81572852);天津市自然科学基金重点项目(12JCZDJC26300);武警后勤学院创新团队科学基金助(WHID201303);武警后勤学院科学技术研究项目(WHZ201202)

摘　　要：人白细胞介素-6(Interleukin 6,IL-6)是一种由多种细胞产生的,具有多种效应的细胞因子。抗IL-6治疗能中和体内IL-6的产生,缓解炎症和贫血,减少急性期蛋白及抗血管生成作用。目前IL-6抑制剂分为抗IL-6单抗(如Siltuximab)和抗IL-6受体单抗(如Tocilizumab)两类。已证明IL-6抑制剂对Castleman病和炎症性疾病(如类风湿性关节炎)有治疗效果且无明显毒副作用。本文主要对IL-6抑制剂的研究进展及其对Castleman病和炎症性疾病治疗的相关效果进行综述。Human IL-6 is a cytokine produced by many cell types that has pleiotropic effects.Anti-IL-6 therapy neutralizes IL-6 production in vivo,reduces inflammation,hepatic acute phase proteins,and anemia and has antiangiogenic effects.Currently IL-6 inhibitors can be divided into two classes：anti-IL6 mAb（Siltuximab） and an anti-IL-6R mAb（Tocilizumab）.IL-6 inhibitors has demonstrated to therapeutic efficacy with drug registration in Castleman disease and inflammatory disease（rheumatoid arthritis） without major toxicity.In this paper,the progress of IL-6 inhibitors research and its effects on Castleman disease and inflammatory disease were reviewed.

关 键 词：白细胞介素-6 炎症性疾病 CASTLEMAN病 

分 类 号：R551[医药卫生—血液循环系统疾病]